Company Overview and News

4
DXCM: A Leader In The Shift From Prick To Click

2018-07-18 seekingalpha
The CGM market is robust and underpenetrated, with a current TAM of approximately $41 billion based on my market estimates.
DXCM PODD AP MDT

2
Buy These 3 Hartford Mutual Funds for Good Returns

2018-07-11 investorplace
The Hartford Financial Services Group (NYSE:HIG) was founded in 1810 and is recognized as a renowned insurance company in the United States. The company believes that “human-centric investing can create solutions and advisor tools that not only strengthen bottom lines but strengthen advisor-client relationships by helping investors better realize their true-life goals.”
HIG HGH PODD HIG.WS

2
Buy These 3 Hartford Mutual Funds for Good Returns

2018-07-10 zacks
The Hartford Financial Services Group, Inc. (HIG - Free Report) was founded in 1810 and is recognized as a renowned insurance company in the United States. The company believes that “human-centric investing can create solutions and advisor tools that not only strengthen bottom lines but strengthen advisor-client relationships by helping investors better realize their true-life goals.”
HIG HGH PODD HIG.WS

1
PODD / Insulet Corp. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us45784p1012_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) INSULET CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 45784P101 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pa
PODD

1
PODD / Insulet Corp. / BlackRock Inc. - null (Passive Investment)

2018-07-10 sec.gov
us45784p1012_070518.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) INSULET CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 45784P101 -------------------------------------------------------- (CUSIP Number) June 30, 2018 -------------------------------------------------------- (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover pa
PODD

2
PODD / Insulet Corp. INSULET CORPORATION 8-K (Current Report)

2018-07-06 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PODD

3
Insulet Omnipod Insulin Pump Finds Favor in British Columbia

2018-07-05 zacks
It seems that Insulet Corporation (PODD - Free Report) is pulling out all the stops to strengthen its international operations. Following its news of commencing direct commercial operations in Europe, the company once again hit headlines with another major development via its Omnipod Insulin Management Systemin Canada.
SYK PODD GHDX

3
Insulet Starts European Direct Operation, Braces Global Base

2018-07-03 zacks
Insulet Corporation (PODD - Free Report) recently announced that it has commenced direct commercial operations in Europe for its Omnipod Insulin Management System. This development is a major breakthrough in the company’s international portfolio. Going forward, Insulet will provide sales, distribution, customer support and product services for its diabetic support system, Omnipod.
SYK ABMD PODD GHDX

7
Insulet Banks on Omnipod's Growing Market Reach, Runs Risks

2018-07-03 zacks
On Jul 2, we initiated a research report on Insulet Corporation (PODD - Free Report) . We are upbeat about the company’s achievement of two milestones with respect to expansion of Omnipod’s market reach, while a tough competitive landscape raises concern. The stock carries a Zacks Rank #3 (Hold).
ALGN SYK PODD GHDX

15
Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies

2018-06-26 zacks
Eli Lilly and Company (LLY - Free Report) along with Boehringer Ingelheim announced positive top-line data from two clinical studies – EASE 2 and EASE 3 – from the phase III EASE program evaluating SGLT2 inhibitor, Jardiance (empagliflozin), in type I diabetes.
ANIP AGLE PODD

304
Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up

2018-06-06 seekingalpha
Iovance Biotherapeutics (NASDAQ:IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2 trial in metastatic melanoma using tumor-infiltrating lymphocytes (‘TIL). These are T cells derived from the patients' tumors.
NKTR DCPH VXRT LOXO NWBO PODD MRSN SHPG BPMC MYL IMMU IDRA IOVA CTMX KITE CYHHZ BMY CYH AMAG GILD NWBOW PTN PDM K JNCE MRK GHDX ALNY

53
New And Old Investing Stories To Be Told

2018-06-01 seekingalpha
This week's Editor's Notes covers a few ideas on the long side that tend to appeal to value investors - the insurance company, the holding company, international growth.
TURN CYH DLTH RL NSEC CMD PODD CMN INGN SMAR CYHHZ SND MELI ABMD

0
PODD / Insulet Corp. FORM SD

2018-05-31 sec.gov
Form SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
PODD

1
PODD / Insulet Corp. INSULET CORPORATION 8-K (Current Report)

2018-05-18 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PODD

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 45784P101